secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2026-01-27T23:59:59+00:00
Accession:  0000320017-26-000008
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata Therapeutics terminates exclusive license for certepetide with Qilu Pharmaceutical
--------------------------------------------------------------------------------

- Mutual termination of 2021 License and Collaboration Agreement with Qilu, effective January 23, 2026.
- Agreement covered research, development, and commercialization of certepetide (CEND-1) in Greater China.
- Lisata was eligible for up to $200M in milestone payments and 10%-15% royalties on net sales.
- Termination does not affect obligations accrued prior to termination or certain surviving provisions.
- No immediate financial impact disclosed; company loses future milestone/royalty potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001726000008/0000320017-26-000008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001726000008/clbs-20260127.htm
  HTML page:      https://secwatch.observer/filing/0000320017-26-000008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer